drugset / Trial / NCT05774886
Implantable Microdevice for TNBC - Pilot Study
NaSingle-groupOpen-labelTreatment
Summary
The goal of this research study is to evaluate the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of a specific drug or combination of drugs as a possible tool to evaluate the effectiveness of several cancer drugs against early stage Triple Negative Breast Cancer (TNBC). The name of the intervention involved in this study is: Implantable Microdevice (IMD)
Timeline
- Start
- 2023-05
- Primary completion
- 2023-09-01
- Completion
- 2028-09-01
Outcome
Outcome not reported
Stopped: “On hold”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Other |
| Subject | Atezolizumab | Monoclonal antibody | — | Other |
| Subject | Capecitabine | Small molecule | — | Other |
| Subject | Carboplatin | Small molecule | — | Other |
| Subject | Cyclophosphamide | Other / unclassified | — | Other |
| Subject | Doxorubicin | Other / unclassified | — | Other |
| Subject | Eribulin | Small molecule | — | Other |
| Subject | Gemcitabine | Small molecule | — | Other |
| Subject | Olaparib | Small molecule | — | Other |
| Subject | Paclitaxel | Small molecule | — | Other |
| Subject | Panobinostat | Small molecule | — | Other |
| Subject | Pembrolizumab | Monoclonal antibody | — | Other |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | Other |
| Subject | Tazemetostat | Small molecule | — | Other |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | — | Other |
| Subject | Venetoclax | Small molecule | — | Other |